Dr. Scott is a Professor in the Department of Pathology at Stanford University and Director of the Stanford Medicine Clinical Genomics Laboratory, where he oversees genomic test innovation and implementation. In addition, Dr. Scott is certified by the American Board of Medical Genetics and Genomics (ABMGG) in Clinical Molecular Genetics and Genomics, and Clinical Cytogenetics, and his research interests include human genomics, pharmacogenomics, cytogenomics, long-read sequencing, and the implementation of genomic medicine. He is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), PharmGKB, PharmCAT, PharmVar, AMP Pharmacogenomics Working Group, International Union of Basic and Clinical Pharmacology (IUPHAR), and other national human genomics consortia (ClinGen, UDN, GREGoR). He has co-authored several CPIC practice guidelines and has published over 140 peer-reviewed manuscripts and book chapters on clinical genomics, pharmacogenomics, and genomic medicine implementation.
Mary Relling, St. Jude
Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.